ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia (AML). However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies in AML are negligible except for those targeting mutant isocitrate dehydrog...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianbiao, Quah, Jessie Yiying, Ng, Yvonne, Chooi, Jing-Yuan, Toh, Sabrina Hui-Min, Lin, Baohong, Tan, Tuan Zea, Hosoi, Hiroki, Osato, Motomi, Seet, Qihui, Ooi, A.G. Lisa, Lindmark, Bertil, McHale, Mark, Chng, Wee-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556493/
https://www.ncbi.nlm.nih.gov/pubmed/33054053
http://dx.doi.org/10.3324/haematol.2019.230482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556493/
https://www.ncbi.nlm.nih.gov/pubmed/33054053
http://dx.doi.org/10.3324/haematol.2019.230482

Ejemplares similares